Cancer Clinical Trials Centre
To lead and support world class clinical and translational cancer research that enables our patients to live longer and better lives.
The infrastructure for clinical cancer research within the Sheffield Cancer Research Centre is primarily located within the Cancer Clinical Trials Centre (CCTC) at Weston Park Hospital. This purpose built clinical research facility (CRF) was established in 1999, and provides an ideal environment, with consulting rooms, treatment suite and sample processing laboratory, for the assessment and treatment of patients on novel therapies. The Experimental Cancer Medicine Centre ECMC) and North Trent Cancer Research Network (NTCRN) are co-ordinated from within the Centre. Additional clinical research active groups with links to the CCTC include surgical and urological oncology and haematological oncology.
The CCTC receives income (£>1.5 million per year) from a variety of sources to support more than 70 staff. Importantly, the WPH Cancer Charity (WPHCC) provides infrastructure funding for the research management team, who both co-ordinate and underpin the many activities of the Centre.
There is a well-established, internationally recognised clinical trials programme across multiple tumour types associated with a consistently high output of publications. Over the past 5 years, more than 4000 patients have been included in National Institute for Health research (NIHR) portfolio studies. Clinical trial participation exceeds 10% of incident cases into NCRN approved trials and overall trial participation is close to 15% of incident cases. In 2010/11, we had our most active year for recruitment with inclusion of >20% of cancer patients into research trials and studies. This is on a background of continued follow-up of many thousands of patients recruited in previous years.
Our research priorities are early phase drug trials, notably in lung cancer, (Penella Woll) melanoma, (Sarah Danson) and breast cancer, including phase III randomised clinical trials across multiple tumour types, development of bone targeted agents (Rob Coleman) linking directly to the bone oncology laboratory research programmes. We also drive the technical developments in planning and delivery of radiotherapy (Martin Robinson and Jim Wild) and survivorship issues including identification and management of late treatment toxicities associated with cancer treatments (Rob Coleman and Richard Ross).
Development priorities include a new “state of the art” research treatment facility adjacent to, and integrated with, the NHS cancer drug treatment facilities at Weston Park Hospital. Funds are available for this to go ahead, with the new facility expected to become available in late 2012.